Chlorphenamine/codeine - Vernalis

Drug Profile

Chlorphenamine/codeine - Vernalis

Alternative Names: CCP-01; Chlorphenamine polistirex/codeine polistirex; Codeine polistirex/chlorphenamine polistirex; Codeine/chlorphenamine; Tuzistra XR

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Tris Pharma; Vernalis
  • Class Antitussives; Morphinans; Opioid analgesics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Common cold; Cough

Most Recent Events

  • 08 Sep 2015 Launched for Cough and Common cold in USA - first global launch (PO)
  • 30 Apr 2015 Registered for Cough and Common cold in USA - First global approval (PO)
  • 15 Sep 2014 PDUFA action date of 30 April 2015 assigned by FDA for chlorphenamine/codeine for common cold/cough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top